A government contract with Aspire was officiated in the late summer of 2018. Textmunication has a 49% stake in Aspire Consulting.
Investors buy into for example, Biotech companies hoping that scientists will patent successful cancer treatments or cures but most fail. It doesn’t mean the company didn’t have intent to do so. Textmunication has not mislead investors and this play is much safer than sectors such as biotech or companies with no cash flow or mounting losses.
Baby steps; this doesn’t all happen overnight. Textmunication is executing on everything they said they would. We will continue to see this going forward if their cash flow is positive. Really anxious to read the next earnings report.
Market Data 
Markets 
AI
